Sopharma AD-Sofia (FRA:3JR) Growth Rank: 2 (As of Sep. 11, 2026) — 78% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:3JR Sopharma AD-Sofia FRA:3JR
68 GF Score
Price €2.49
GF Value €1.91
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Sopharma AD-Sofia Growth Rank?

Sopharma AD-Sofia FRA:3JR +8.26% 68 Growth Rank is 2 as of Sep. 11, 2026, which is 78% below its 10-year median of 9.00. GuruFocus rates FRA:3JR with a GF Score™ of 68/100 and a GF Value™ of €1.91 (Modestly Overvalued). The stock has 3 warning signs investors should review.

Sopharma AD-Sofia has the Growth Rank of 2.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Sopharma AD-Sofia Growth Rank Related Terms

FRA:3JR vs MCK, COR, CAH: Growth Rank Comparison

For the Medical Distribution subindustry, Sopharma AD-Sofia's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sopharma AD-Sofia Growth Rank vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's Growth Rank distribution charts can be found below:

* The bar in red indicates where Sopharma AD-Sofia's Growth Rank falls into.


FRA:3JR
68GF Score
Sopharma AD-Sofia FRA:3JR
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 2 mean?
Sopharma AD-Sofia (FRA:3JR) has a Growth Rank of 2 as of Sep. 11, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Sopharma AD-Sofia and its competitors. This is 78% below median its historical median of 9.00. Over the past decade, Sopharma AD-Sofia's Growth Rank has ranged from 1.00 to 10.00.
Is Sopharma AD-Sofia's Growth Rank too high?
Sopharma AD-Sofia's current Growth Rank of 2 is 78% below median its 10-year median of 9.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Sopharma AD-Sofia has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's Growth Rank compare to MCK and COR?
Sopharma AD-Sofia's Growth Rank of 2 can be compared against companies in the Medical Distribution industry. Historically, Sopharma AD-Sofia's own Growth Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Medical Distribution company?
A good Growth Rank depends on the Medical Distribution industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Sopharma AD-Sofia and its competitors. Sopharma AD-Sofia's current Growth Rank is 2, which is 78% below median its own 10-year median of 9.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (FRA:3JR) is currently considered Modestly Overvalued. The stock's GF Value™ is €1.91, compared to a current price of €2.49 — trading 30.4% above its estimated fair value. The current Growth Rank is 2, which is 78% below median its 10-year median of 9.00. Sopharma AD-Sofia's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Sopharma AD-Sofia (FRA:3JR), the current Growth Rank is 2 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sopharma AD-Sofia (FRA:3JR) Overvalued in 2026?

Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be overvalued. The current stock price of €2.49 is trading 30.4% above its estimated GF Value™ of €1.91. GuruFocus considers Sopharma AD-Sofia to be Modestly Overvalued.

Key valuation signals for FRA:3JR:

  • Growth Rank: 2 (78% below median its 10-year median of 9.00)
  • GF Value™: €1.91 vs. price of €2.49 (30.4% above fair value)
  • GF Score™: 68/100 with 3 warning signs

No single metric tells the full story. See the FRA:3JR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sopharma AD-Sofia Business Description

Other Exchanges SPH:PolandSFA:Bulgaria
Address 5 Lachezar Stanchev Street, Sopharma Business Towers, Building A, Floor 12, Sofia, BGR, 1756
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
68GF Score

Get the complete analysis for FRA:3JR

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.49
Price
€1.91
GF Value